RESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
The proteomics platform advances the Moon Shots Program by providing state-of-the-art instruments, specialized expertise and other resources needed to sift through thousands of cancer-related proteins. The goal is to help investigators identify which proteins are useful for advances in diagnostics, imaging or targets for various types of treatments, from immunotherapies to small molecules.
Additional goals of the platform include determining biologically relevant doses, identifying biomarkers of sensitivity and resistance, and characterizing adaptive responses as we pursue the potential of combining drug targets.
Sam Hanash, M.D, Ph.D.
Professor of Clinical Cancer Prevention Research
Proteomics activities have launched for multiple moon shots. Examples of how the platform is working with moon shot investigators include:
- AML/MDS – Detailed analyses of pretreatment and post-refractory treatment patient samples are revealing mechanisms of resistance to methylation inhibitors, markers of resistance and novel targets for therapeutics.
- Prostate cancer – Most prostate cancers treated with androgen deprivation therapy (ADT) become resistant to the effects of ADT/androgen signaling inhibitors. To address this problem, mechanisms of resistance are being defined, and novel targets for therapeutics are being identified via proteomic analysis of ADT-resistant and/or pro-metastatic prostate cancer cells.
- Lung cancer – A marker panel is being assembled to complement CT screening for the early detection of lung cancer.
- Breast cancer – To effectively determine which patients with early breast cancer will not require chemotherapy, a robust four-protein assay has been developed and transitioned into the clinic.
cancer – Studies are underway to identify novel markers that
complement CA125 for the early detection of ovarian cancer.